From blood to regenerative tissue : How autologous platelet-rich fibrin can be combined with other materials to ensure controlled drug and growth factor release

dc.contributor.authorEgle, Karina
dc.contributor.authorSalma, Ilze
dc.contributor.authorDubnika, Arita
dc.contributor.institutionRīga Stradiņš University
dc.date.accessioned2021-12-17T11:25:01Z
dc.date.available2021-12-17T11:25:01Z
dc.date.issued2021-11-01
dc.descriptionFunding Information: This research was funded by the Latvian Council of Science research project No. lzp-2020/1-0054 ?Development of antibacterial autologous fibrin matrices in maxillofacial surgery (MATRI-X)?. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
dc.description.abstractThe purpose of this review is to examine the latest literature on the use of autologous platelet-rich fibrin as a drug and growth factor carrier system in maxillofacial surgery. Autologous platelet-rich fibrin (PRF) is a unique system that combines properties such as biocompatibility and biodegradability, in addition to containing growth factors and peptides that provide tissue regeneration. This opens up new horizons for the use of all beneficial ingredients in the blood sample for biomedical purposes. By itself, PRF has an unstable effect on osteogenesis: therefore, advanced approaches, including the combination of PRF with materials or drugs, are of great interest in clinics. The main advantage of drug delivery systems is that by controlling drug release, high drug concentrations locally and fewer side effects within other tissue can be achieved. This is especially important in tissues with limited blood supply, such as bone tissue compared to soft tissue. The ability of PRF to degrade naturally is considered an advantage for its use as a “warehouse” of controlled drug release systems. We are focusing on this concentrate, as it is easy to use in manipulations and can be delivered directly to the surgical site. The target audience for this review are researchers and medical doctors who are involved in the development and research of PRFs further studies. Likewise, surgeons who use PRF in their work to treat patients and who advice patients to take the medicine orally.en
dc.description.statusPeer reviewed
dc.format.extent1546488
dc.identifier.citationEgle, K, Salma, I & Dubnika, A 2021, 'From blood to regenerative tissue : How autologous platelet-rich fibrin can be combined with other materials to ensure controlled drug and growth factor release', International Journal of Molecular Sciences, vol. 22, no. 21, 11553. https://doi.org/10.3390/ijms222111553
dc.identifier.doi10.3390/ijms222111553
dc.identifier.issn1661-6596
dc.identifier.urihttps://dspace.rsu.lv/jspui/handle/123456789/7057
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85117897094&partnerID=8YFLogxK
dc.language.isoeng
dc.relation.ispartofInternational Journal of Molecular Sciences
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAutologous growth factors
dc.subjectCarrier systems
dc.subjectDrug delivery
dc.subjectEndogenous growth factors
dc.subjectPlatelet concentrates
dc.subjectPlatelet-rich fibrin
dc.subjectTissue engineering
dc.subject1.4 Chemical sciences
dc.subject3.2 Clinical medicine
dc.subject1.1. Scientific article indexed in Web of Science and/or Scopus database
dc.subjectCatalysis
dc.subjectMolecular Biology
dc.subjectSpectroscopy
dc.subjectComputer Science Applications
dc.subjectPhysical and Theoretical Chemistry
dc.subjectOrganic Chemistry
dc.subjectInorganic Chemistry
dc.titleFrom blood to regenerative tissue : How autologous platelet-rich fibrin can be combined with other materials to ensure controlled drug and growth factor releaseen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/systematicreview

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
From_blood_to_regenerative_tissue.pdf
Size:
1.47 MB
Format:
Adobe Portable Document Format